bioAffinity Technologies' laboratory subsidiary, Precision Pathology Laboratory Services, retains prestigious College of American Pathologists (CAP) accreditation, signifying adherence to high standards of quality and safety in laboratory services.
The CAP accreditation reflects the commitment to excellence and quality in delivering noninvasive diagnostic services, including the CyPath ® Lung test.
CAP Accreditation
The College of American Pathologists (CAP) accreditation highlights the commitment to high-quality standards in laboratory services.
CyPath ® Lung Test
The CyPath ® Lung test meets the demand for noninvasive diagnostic solutions for early-stage lung cancer diagnosis.
Market Projections
The projected growth of the U.S. lung cancer diagnostics market to $10.4 billion by 2034 indicates significant growth potential in this segment.
Acquisition Impact
The acquisition of Precision Pathology Laboratory Services reinforces the growth trajectory of the CyPath ® Lung diagnostic test.
- The CAP accreditation reinforces the credibility of bioAffinity Technologies' laboratory services, ensuring quality and accuracy in diagnostic testing.
- CyPath ® Lung's ability to detect lung cancer at an early stage aligns with the growing demand for noninvasive diagnostic solutions in the healthcare industry.
- The projected growth of the U.S. lung cancer diagnostics market underscores the importance of CyPath ® Lung in addressing the critical healthcare need for early-stage lung cancer detection.
Maintaining the College of American Pathologists (CAP) accreditation underscores bioAffinity Technologies' dedication to providing high-quality laboratory services and innovative noninvasive diagnostic solutions to improve patient outcomes. The optimistic market projections for the lung cancer diagnostics market further affirm the value of CyPath ® Lung in the healthcare landscape.